- Rallybio announced Chief Medical Officer Steven Ryder will leave effective immediately.
- Departure follows Ryder’s tenure in role since January 2019.
- Equity awards remain outstanding under terms tied to pending business combination with Candid Therapeutics.
- Options will remain exercisable until 90 days following closing of merger.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rallybio Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-022385), on March 31, 2026, and is solely responsible for the information contained therein.
Comments